Natural product modulators to overcome multidrug resistance in cancer

Nutrition and Cancer

Volumn 67, Issue 3, 2015, Pages 411-423

  Cort, Aysegul ^a   Ozben, Tomris ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CURCUMIN; DAIDZEIN; DAUNORUBICIN; DOXORUBICIN; FUMITREMORGIN C; GENISTEIN; HEPTANE DERIVATIVE; HERBACEOUS AGENT; LIPOSOME; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; NATURAL PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUERCETIN; RESVERATROL; RETINOID X RECEPTOR; SILYMARIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VINBLASTINE; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; BIOLOGICAL PRODUCT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SENSITIVITY; DRUG TRANSPORT; HUMAN; MULTIDRUG RESISTANCE; DRUG RESISTANCE; NEOPLASMS; PHYSIOLOGY;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL PRODUCTS; CURCUMIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENISTEIN; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEINS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 84926515395     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.1002624     Document Type: Article

References (153)

1. Persidis A: Cancer multidrug resistance. Nat Biotechnol 17, 94-95, 1999.
2. Baguley BC: Multidrug resistance in cancer. Methods Mol Biol 596, 1-14, 2010.
3. Schinkel AH and Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55, 3-29, 2003.
4. Wu CP, Ohnuma S, and Ambudkar SV: Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12, 609-620, 2011.
5. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42, 1007-1017, 2001.
6. Sharom FJ: The P-glycoprotein multidrug transporter. Essays Biochem 50, 161-178, 2011.
7. Beaulieu E, Demeule M, Ghitescu L, and Beliveau R: P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326 (Pt 2), 539-544, 1997.
8. Amin ML: P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7, 27-34, 2013.
9. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, et al.: Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10, RA5-R14, 2004.
10. Martins A, Vasas A, Schelz Z, Viveiros M, Molnar J, et al.: Constituents of Carpobrotus edulis inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. Anticancer Res 30, 829-835, 2010.
11. Hipfner DR, Almquist KC, Leslie EM, Gerlach JH, Grant CE, et al.: Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J Biol Chem 272, 23623-23630, 1997.
12. Hipfner DR, Deeley RG, and Cole SP: Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461, 359-376, 1999.
13. Renes J, de Vries EG, Nienhuis EF, Jansen PL, and Muller M: ATP-And glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 126, 681-688, 1999.
14. Bagrij T, Klokouzas A, Hladky SB, and Barrand MA: Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-Associated protein, MRP1. Biochem Pharmacol 62, 199-206, 2001.
15. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, et al.: Role of glutathione in the export of compounds from cells by the multidrug-resistance-Associated protein. Proc Natl Acad Sci U S A 92, 7690-7694, 1995.
16. Akan I, Akan S, Akca H, Savas B, and Ozben T: Multidrug resistanceassociated protein 1 (MRP1) mediated vincristine resistance: effects of N-Acetylcysteine and Buthionine sulfoximine. Cancer Cell Int 5, 22, 2005.
17. Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, et al.: Overexpression of the gene encoding the multidrug resistance-Associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A 91, 13033-13037, 1994.
18. Kearns PR and Hall AG: Microtiter plate technique for the measurement of glutathione in fresh and cryopreserved lymphoblasts using the enzyme recycling method. Methods Mol Med 28, 83-90, 1999.
19. Loe DW, Almquist KC, Deeley RG, and Cole SP: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271, 9675-9682, 1996.
20. Loe DW, Deeley RG, and Cole SP: Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 58, 5130-5136, 1998.
21. Yan CY, Ferrari G, and Greene LA: N-Acetylcysteine-promoted survival of PC12 cells is glutathione-independent but transcription-dependent. J Biol Chem 270, 26827-26832, 1995.
22. Loe DW, Deeley RG, and Cole SP: Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293, 530-538, 2000.
23. Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, and Cole SP: Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol 59, 1171-1180, 2001.
24. Krishnamurthy P and Schuetz JD: Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46, 381-410, 2006.
25. Cervenak J, Andrikovics H, Ozvegy-Laczka C, Tordai A, Nemet K, et al.: The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett 234, 62-72, 2006.
26. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, et al.: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99, 15649-15654, 2002.
27. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, et al.: The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-Amino-1-methyl-6-phenylimidazo [4,5-b] pyridine. Cancer Res; 63, 6447-6452, 2003.
28. Kellen JA: The reversal of multidrug resistance: an update. J Exp Ther Oncol 3, 5-13, 2003.
29. Ullah MF: Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev 9, 1-6, 2008.
30. Yang K, Wu J, and Li X: Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends 2, 137-146, 2008.
31. He SM, Li R, Kanwar JR, and Zhou SF: Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 18, 439-481, 2011.
32. Ferry DR, Traunecker H, and Kerr DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A, 1070-1081, 1996.
33. Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165, 2003.
34. Robert J and Jarry C: Multidrug resistance reversal agents. J Med Chem 46, 4805-4817, 2003.
35. Ozben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580, 2903-2909, 2006.
36. Bogush TA, Zabotina TN, Bogush EA, Chmutin EF, Komov DV, et al.: New approach to vital analysis of functional activity in ABC transporters (markers for multidrug resistance) in solid tumors by the method of flow cytofluorometry. Bull Exp Biol Med 135, 482-488, 2003.
37. Twentyman PR and Bleehen NM: Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer; 27, 1639-1642, 1991.
38. Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11, 265-283, 2000.
39. Bohme M, Buchler M, Muller M, and Keppler D: Differential inhibition by cyclosporins of primary-Active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333, 193-196, 1993.
40. Song S, Suzuki H, Kawai R, Tanaka C, Akasaka I, et al.: Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab Dispos 26, 1128-1133, 1998.
41. Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, et al.: Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26, 2674-2682, 2008.
42. Saraswathy M and Gong S: Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 31, 1397-1407, 2013.
43. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, et al.: P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59, 3944-3948, 1999.
44. Bates S, Kang M, Meadows B, Bakke S, Choyke P, et al.: A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 92, 1577-1590, 2001.
45. Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, et al.: The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26, 802-811, 1998.
46. Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, et al.: The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 7, 1610-1617, 2001.
47. Liscovitch M and Lavie Y: Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5, 349-355, 2002.
48. Mayur YC, Peters GJ, Prasad VV, Lemo C, and Sathish NK: Design of new drug molecules to be used in reversing multidrug resistance in cancer cells. Curr Cancer Drug Targets 9, 298-306, 2009.
49. Martelli C, Alderighi D, Coronnello M, Dei S, Frosini M, et al.: N,N-bis (cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors. J Med Chem 52, 807-817, 2009.
50. Martelli C, Coronnello M, Dei S, Manetti D, Orlandi F, et al.: Structureactivity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. J Med Chem 53, 1755-1762, 2010.
51. Lee CH: Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Curr Med Chem Anticancer Agents 4, 43-52, 2004.
52. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, et al.: Discovery and characterization of OC144-093, a novel inhibitor of Pglycoprotein-mediated multidrug resistance. Cancer Res 60, 2964-2972, 2000.
53. Nobili S, Landini I, Giglioni B, and Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7, 861-879, 2006.
54. Lee CH: Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 596, 325-340, 2010.
55. Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, et al.: Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116, 4077-4085, 2010.
56. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219-234, 2006.
57. Polgar O and Bates SE: ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Trans 33, 241-245, 2005.
58. Shukla S, Wu CP, and Ambudkar SV: Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 4, 205-223, 2008.
59. Leonard GD, Polgar O, and Bates SE: ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3, 1652-1659, 2002.
60. Molnar J, Engi H, Hohmann J, Molnar P, Deli J, et al.: Reversal of multidrug resitance by natural substances from plants. Curr Top Med Chem 10, 1757-1768, 2010.
61. Gottesman MM, Fojo T, and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48-58, 2002.
62. Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, et al.: Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer 12, 137, 2013.
63. Eckford PD and Sharom FJ: Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 47, 13686-13698, 2008.
64. Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304, 1258-1267, 2003.
65. Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, et al.: Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59, 307-322, 2002.
66. Boumendjel A, Di Pietro A, Dumontet C, and Barron D: Recent advances in the discovery of flavonoids and analogs with high-Affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 22, 512-529, 2002.
67. Hooijberg JH, Broxterman HJ, Scheffer GL, Vrasdonk C, Heijn M, et al.: Potent interaction of flavopiridol with MRP1. Br J Cancer 81, 269-276, 1999.
68. van Zanden JJ, Geraets L, Wortelboer HM, van Bladeren PJ, Rietjens IM, et al.: Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol 67, 1607-1617, 2004.
69. Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, and Barrand MA: Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 272, 4725-4740, 2005.
70. Versantvoort CH, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, et al.: Genistein modulates the decreased drug accumulation in non-Pglycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68, 939-946, 1993.
71. Lorendeau D, Dury L, Genoux-Bastide E, Lecerf-Schmidt F, Simoes-Pires C, et al.: Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux. Biochem Pharmacol 90, 235-245, 2014.
72. Lo YL and Wang W: Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro. Chem Biol Interact 205, 188-197, 2013.
73. Joshi G, Hardas S, Sultana R, St Clair DK, Vore M, et al.: Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res 85, 497-503, 2007.
74. Ma H, Zhou H, Li P, Song X, Miao X, et al.: Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia. Biochim Biophys Acta 1842, 1681-1692, 2014.
75. Kim JH, Chen C, and Tony KongAN: Resveratrol inhibits genisteininduced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Arch Biochem Biophys 512, 160-166, 2011.
76. Bobrowska-Hagerstrand M, Wrobel A, Mrowczynska L, Soderstrom T, Shirataki Y, et al.: Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-Activity relationship study. Oncol Res 13, 463-469, 2003.
77. Lania-Pietrzak B, Michalak K, Hendrich AB, Mosiadz D, Grynkiewicz G, et al.: Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids. Life Sci 77, 1879-1891, 2005.
78. Wesolowska O, Hendrich AB, Laniapietrzak B, Wisniewski J, Molnar J, et al.: Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids. Cell Mol Biol Lett 14, 199-221, 2009.
79. Wesolowska O, Wisniewski J, Sroda K, Krawczenko A, Bielawska-Pohl A, et al.: 8-Prenylnaringenin is an inhibitor of multidrug resistance-Associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol 644, 32-40, 2010.
80. Critchfield JW, Welsh CJ, Phang JM, and Yeh GC: Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48, 1437-1445, 1994.
81. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, et al.: Quercetin potentiates the effect of adriamycin in a multidrugresistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34, 459-464, 1994.
82. Versantvoort CH, Rhodes T, and Twentyman PR: Acceleration of MRPassociated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer 74, 1949-1954, 1996.
83. Shapiro AB and Ling V: Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 53, 587-596, 1997.
84. Bansal T, Jaggi M, Khar RK, and Talegaonkar S: Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12, 46-78, 2009.
85. Wesolowska O: Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-Associated transporters, P-glycoprotein and MRP1. Acta Biochim Pol 58, 433-48, 2011.
86. Aggarwal BB, Kumar A, and Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23, 363-398, 2003.
87. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, and Ambudkar SV: Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296, 85-95, 2007.
88. Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, et al.: Curcumin enhances the efficacy of chemotherapy by tailoring p65NFkappaB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem 286, 42232-42247, 2011.
89. Ruiz de Almodovar C, Ruiz-Ruiz C, Munoz-Pinedo C, Robledo G, and Lopez-Rivas A: The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. Oncogene 20, 7128-7133, 2001.
90. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, et al.: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271, 12687-12690, 1996.
91. Zauli G and Secchiero P: The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 17, 245-257, 2006.
92. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682, 1995.
93. Park SJ, Wu CH, Choi MR, Najafi F, Emami A, et al.: P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem Pharmacol 72, 293-307, 2006.
94. Shankar S, Ganapathy S, Chen Q, and Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7, 16, 2008.
95. Wahl H, Tan L, Griffith K, Choi M, and Liu JR: Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 105, 104-112, 2007.
96. Ganta S and Amiji M: Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6, 928-939, 2009.
97. Yan YD, Kim DH, Sung JH, Yong CS, and Choi HG: Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 399, 116-120, 2010.
98. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895-2900, 2001.
99. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14, 4491-4499, 2008.
100. Novakovic M, Pesic M, Trifunovic S, Vuckovic I, Todorovic N, et al.: Diarylheptanoids from the bark of black alder inhibit the growth of sensitive and multi-drug resistant non-small cell lung carcinoma cells. Phytochemistry 97, 46-54, 2014.
101. Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, et al.: Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840, 615-625, 2014.
102. Kwatra D, Venugopal A, Standing D, Ponnurangam S, Dhar A, et al.: Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance. J Pharm Sci 102, 4444-4454, 2013.
103. Sun L, Chen W, Qu L, Wu J, and Si J: Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and Pglycoprotein expression. Mol Med Rep 8, 1883-1887, 2013.
104. Wei L, Chen P, Chen Y, Shen A, Chen H, et al.: Pien Tze Huang suppresses the stem-like side population in colorectal cancer cells. Mol Med Rep 9, 261-266, 2014.
105. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, and van Tellingen O: The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 53, 173-178, 2004.
106. Jianga Z, Jina T, Gaoa F, Liua J, Zhongb J, et al.: Effects of Ganoderic acid Me on inhibiting multidrug resistance and inducing apoptosis in multidrug resistant colon cancer cells. Process Biochemistry 46, 1307-1314, 2011.
107. Zhu H, Liu Z, Tang L, Liu J, Zhou M, et al.: Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. Eur J Pharmacol 696, 43-53, 2012.
108. Nabekura T, Yamaki T, Ueno K, Kitagawa S: Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun 369, 363-368, 2008.
109. Yoshida N, Takada T, Yamamura Y, Adachi I, Suzuki H, et al.: Inhibitory effects of terpenoids on multidrug resistance-Associated protein 2-And breast cancer resistance protein-mediated transport. Drug Metab Dispos 36, 1206-1211, 2008.
110. Ahmed-Belkacem A, Macalou S, Borrelli F, Capasso R, Fattorusso E, et al.: Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J Med Chem 50, 1933-1938, 2007.
111. Imai Y, Tsukahara S, Asada S, and Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64, 4346-4352, 2004.
112. Tamaki H, Satoh H, Hori S, Ohtani H, and Sawada Y: Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab Pharmacokinet 25, 170-179, 2010.
113. Rabindran SK, Ross DD, Doyle LA, Yang W, and Greenberger LM: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60, 47-50, 2000.
114. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, et al.: Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1, 417-425, 2002.
115. Zou L, Harkey MR, and Henderson GL: Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71, 1579-1589, 2002.
116. Umathe SN, Dixit PV, Kumar V, Bansod KU, and Wanjari MM: Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition. Biochem Pharmacol 75, 1670-1676, 2008.
117. Gonzalez-Vallinas M, Molina S, Vicente G, de la Cueva A, Vargas T, et al.: Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. Pharmacol Res 72, 61-68, 2013.
118. Abraham I, El Sayed K, Chen ZS, and Guo H: Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs 10, 2312-2321, 2012.
119. Wei DD, Wang JS, and Kong LY: Reversal effects of components from the fruits of Illicium simonsii on human Adriamycin-resistant MCF-7 and 5-fluorouracil-resistant Bel7402 cells. Phytother Res 26, 562-567, 2012.
120. Giovannetti E, Erozenci A, Smit J, Danesi R, and Peters GJ: Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 81, 103-122, 2012.
121. Kruser TJ and Wheeler DL: Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316, 1083-1100, 2010.
122. Song L, Li Y, Li W, Wu S, and Li Z: MiR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of coppertransporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 115, 1234-1242, 2014.
123. Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, et al.: By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. Leuk Res 38, 121-130, 2014.
124. Abbasi M, Lavasanifar A, and Uludag H: Recent attempts at RNAimediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev 33, 33-53, 2013.
125. Feng Y, Hu Y, Cen J, Darshika KN, Fang W, et al.: HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. Eur J Pharmacol 712, 53-59, 2013.
126. Ame JC, Spenlehauer C, and de Murcia G: The PARP superfamily. Bioessays 26, 882-893, 2004.
127. Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26, 3785-3790, 2008.
128. Annunziata CM and O'Shaughnessy J: Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 16, 4517-4526, 2010.
129. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-ofconcept trial. Lancet 376, 245-251, 2010.
130. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-ofconcept trial. Lancet 376, 235-244, 2010.
131. Curtin NJ: PARP inhibitors for cancer therapy. Expert Rev Mol Med 7, 1-20, 2005.
132. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, et al.: Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6, 2860-2867, 2000.
133. Clark CC, Weitzel JN, and O'Connor TR: Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 11, 1948-1958, 2012.
134. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, et al.: The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 9, 144-155, 2012.
135. Zhang J, Kan Y, Tian Y, and Wang Z: Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13 cells. Indian J Med Res 137, 527-532, 2013.
136. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, et al.: Cisplatin resistance associated with PARP hyperactivation. Cancer Res 73, 2271-2280, 2013.
137. Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, et al.: Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 229, 422-429, 2013.
138. Yan Y, Bjornmalm M, and Caruso F: Particle carriers for combating multidrug-resistant cancer. ACS Nano 7, 9512-9517, 2013.
139. Markman JL, Rekechenetskiy A, Holler E, and Ljubimova JY: Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 65, 1866-1879, 2013.
140. Wang AZ, Langer R, and Farokhzad OC: Nanoparticle delivery of cancer drugs. Annu Rev Med 63, 185-198, 2012.
141. Torchilin VP: Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents. Ther Deliv 1, 257-272, 2010.
142. Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, et al.: Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res 24, 2402-2411, 2007.
143. Mattheolabakis G, Rigas B, and Constantinides PP: Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond) 7, 1577-1590, 2012.
144. Apte A, Koren E, Koshkaryev A, and Torchilin VP: Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models. Cancer Biol Ther 15, 69-80, 2014.
145. Zhu H, Chen H, Zeng X, Wang Z, Zhang X, et al.: Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials 35, 2391-2400, 2014.
146. Zeng X, Morgenstern R, and Nystrom AM: Nanoparticle-directed subcellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance. Biomaterials 35, 1227-1239, 2014.
147. Ma X, Zhao Y, and Ng KW: Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chemistry 19, 15593-15603, 2013.
148. Webster DM, Sundaram P, and Byrne ME: Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 84, 1-20, 2013.
149. Cheng Q, Blais MO, Harris G, and Jabbarzadeh E: PLGA-carbon nanotube conjugates for intercellular delivery of caspase-3 into osteosarcoma cells. PLoS One 8, e81947, 2013.
150. Fabbro C, Ali-Boucetta H, Da RosT, Kostarelos K, Bianco A, et al.: Targeting carbon nanotubes against cancer. Chem Commun (Camb) 48, 3911-3926, 2012.
151. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Jr., Gannon WE, et al.: Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16, 6139-6149, 2010.
152. Yang Y, Zhang Z, Li S, Ye X, Li X, et al.: Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis. Fitoterapia 92C, 133-147, 2013.
153. Rather MA, Bhat BA, and Qurishi MA: Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down? Phytomedicine 21, 1-14, 2013.